Comparing the Efficacy of Methadone and Tincture of Opium in Controlling Agitation Caused by Withdrawal Syndrome in Opium-Addicted Patients in the Intensive Care Unit: A Randomized Trial Study.
Intensive care units
Methadone
Opium dependence
Journal
Addiction & health
ISSN: 2008-4633
Titre abrégé: Addict Health
Pays: Iran
ID NLM: 101582275
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
entrez:
13
8
2020
pubmed:
13
8
2020
medline:
13
8
2020
Statut:
ppublish
Résumé
Few studies have been conducted regarding the comparison of the efficacy of methadone and tincture of opium (TOP) in controlling agitation induced by withdrawal syndrome. Therefore, the current randomized trial study is carried out with the aim to evaluate comparisons on the efficacy of methadone and TOP in controlling agitation caused by withdrawal syndrome in opium addicted patients in the intensive care units (ICUs). This clinical trial study was conducted on 60 patients admitted to ICU of Shahid Bahonar Hospital, Kerman, Iran. After classification of the patients into two groups, the first and second groups consumed methadone syrup (5 mg/ml) and TOP (10 mg/ml), respectively. Agitation in these patients was assessed through the Richmond Agitation-Sedation Scale (RASS). Vital signs were also assessed. Paired sample t-test and independent t-test were used for data analysis. In the current study, the administered dose of methadone and TOP was 36.17 ± 26.99 and 112.67 ± 102.74 mg, respectively (P < 0.010). Methadone administration led to a significant decrease of the patients' vital signs, including systolic blood pressure, heart rate, respiratory rate, and Glasgow Coma Scale (GCS) (P < 0.05). Though TOP administration decreased systolic blood pressure and GCS significantly (P < 0.05), it had no effect on patients' diastolic blood pressure, body temperature, heart rate, and respiratory rate (P > 0.05). In total, no significant difference was detected between two groups regarding vital signs (P > 0.05). However, a significant difference was seen between methadone and TOP groups in terms of RASS score (P < 0.01). According to the results of the current study, lower dose of methadone, compared to TOP, could control agitation caused by opium withdrawal symptoms.
Sections du résumé
BACKGROUND
BACKGROUND
Few studies have been conducted regarding the comparison of the efficacy of methadone and tincture of opium (TOP) in controlling agitation induced by withdrawal syndrome. Therefore, the current randomized trial study is carried out with the aim to evaluate comparisons on the efficacy of methadone and TOP in controlling agitation caused by withdrawal syndrome in opium addicted patients in the intensive care units (ICUs).
METHODS
METHODS
This clinical trial study was conducted on 60 patients admitted to ICU of Shahid Bahonar Hospital, Kerman, Iran. After classification of the patients into two groups, the first and second groups consumed methadone syrup (5 mg/ml) and TOP (10 mg/ml), respectively. Agitation in these patients was assessed through the Richmond Agitation-Sedation Scale (RASS). Vital signs were also assessed. Paired sample t-test and independent t-test were used for data analysis.
FINDINGS
RESULTS
In the current study, the administered dose of methadone and TOP was 36.17 ± 26.99 and 112.67 ± 102.74 mg, respectively (P < 0.010). Methadone administration led to a significant decrease of the patients' vital signs, including systolic blood pressure, heart rate, respiratory rate, and Glasgow Coma Scale (GCS) (P < 0.05). Though TOP administration decreased systolic blood pressure and GCS significantly (P < 0.05), it had no effect on patients' diastolic blood pressure, body temperature, heart rate, and respiratory rate (P > 0.05). In total, no significant difference was detected between two groups regarding vital signs (P > 0.05). However, a significant difference was seen between methadone and TOP groups in terms of RASS score (P < 0.01).
CONCLUSION
CONCLUSIONS
According to the results of the current study, lower dose of methadone, compared to TOP, could control agitation caused by opium withdrawal symptoms.
Identifiants
pubmed: 32782729
doi: 10.22122/ahj.v12i2.259
pii: AHJ-12-069
pmc: PMC7395929
doi:
Types de publication
Journal Article
Langues
eng
Pagination
69-76Informations de copyright
© 2020 Kerman University of Medical Sciences.
Références
Arch Iran Med. 2015 Sep;18(9):567-71
pubmed: 26317596
Glob J Health Sci. 2014 Feb 22;6(3):97-103
pubmed: 24762351
BMC Public Health. 2013 Apr 10;13:325
pubmed: 23575143
Am J Hosp Palliat Care. 2011 Mar;28(2):135-40
pubmed: 20555039
J Pain Symptom Manage. 1997 Sep;14(3):157-67
pubmed: 9291702
J Subst Abuse Treat. 1994 Nov-Dec;11(6):565-8
pubmed: 7884840
East Mediterr Health J. 2009 Mar-Apr;15(2):425-31
pubmed: 19554990
Addict Health. 2019 Jan;11(1):11-17
pubmed: 31308905
Addict Health. 2013 Summer-Autumn;5(3-4):90-4
pubmed: 24494164
J Clin Oncol. 1998 Oct;16(10):3216-21
pubmed: 9779694
Br J Clin Pharmacol. 2004 Nov;58(5):536-41
pubmed: 15521902
Arch Iran Med. 2017 Apr;20(4):205-210
pubmed: 28412823
J Addict Dis. 2016;35(1):8-14
pubmed: 26566681
Lancet. 1999 Jan 16;353(9148):221-6
pubmed: 9923893
Pharmacol Rev. 2013 Sep 27;65(4):1257-317
pubmed: 24076545
Adv Neonatal Care. 2005 Oct;5(5):265-72
pubmed: 16202968
Acta Med Hist Adriat. 2013;11(1):101-12
pubmed: 23883087
Br J Clin Pharmacol. 2008 Nov;66(5):640-7
pubmed: 19032172
Am J Respir Crit Care Med. 2002 Nov 15;166(10):1338-44
pubmed: 12421743
Arch Iran Med. 2014 Jan;17(1):2-6
pubmed: 24444058
Clin Pharmacol Ther. 1999 Jun;65(6):685-94
pubmed: 10391674